Global HER2-Positive Breast Cancer Market by Treatment Type (Chemotherapy, Targeted Therapy Immunotherapy), by End User (Specialty Clinics, Homecare, Hospitals), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “HER2-Positive Breast Cancer Market research report which is segmented by Treatment Type (Chemotherapy, Targeted Therapy Immunotherapy), by End User (Specialty Clinics, Homecare, Hospitals), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Players/Companies Bayer AG, Fresenius Kabi AG, F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals Industries Ltd., Baxter, Mylan N.V., GlaxoSmithKline plc., Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, AstraZeneca, Novartis AG”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | HER2-Positive Breast Cancer Market Research Report |
| By Treatment Type | Chemotherapy, Targeted Therapy Immunotherapy |
| By End User | Specialty Clinics, Homecare, Hospitals |
| By Route of Administration | Oral, Parenteral |
| By Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy |
| By Companies | Bayer AG, Fresenius Kabi AG, F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals Industries Ltd., Baxter, Mylan N.V., GlaxoSmithKline plc., Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, AstraZeneca, Novartis AG |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 214 |
| Number of Tables & Figures | 150 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global HER2-Positive Breast Cancer Market Report Segments:
The market is segmented by Treatment Type (Chemotherapy, Targeted Therapy Immunotherapy), by End User (Specialty Clinics, Homecare, Hospitals), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
HER2-Positive Breast Cancer Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the HER2-Positive Breast Cancer Market
Overview of the regional outlook of the HER2-Positive Breast Cancer Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The HER2-Positive Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of HER2-Positive Breast Cancer Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Chemotherapy
2. Targeted Therapy Immunotherapy
7. By End User:1. Specialty Clinics
2. Homecare
3. Hospitals
8. By Route of Administration:1. Oral
2. Parenteral
9. By Distribution Channel:1. Hospital Pharmacy
2. Retail Pharmacy
3. Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HER2-Positive Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the HER2-Positive Breast Cancer Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HER2-Positive Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 HER2-Positive Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 HER2-Positive Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the HER2-Positive Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global HER2-Positive Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 HER2-Positive Breast Cancer Market Size and Y-o-Y Growth
4.5.2 HER2-Positive Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Treatment Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Treatment Type
5.1.2 Basis Point Share (BPS) Analysis by Treatment Type
5.1.3 Absolute $ Opportunity Assessment by Treatment Type
5.2 HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy Immunotherapy
5.3 Market Attractiveness Analysis by Treatment Type
Chapter 6 Global HER2-Positive Breast Cancer Market Analysis and Forecast by End User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End User
6.1.2 Basis Point Share (BPS) Analysis by End User
6.1.3 Absolute $ Opportunity Assessment by End User
6.2 HER2-Positive Breast Cancer Market Size Forecast by End User
6.2.1 Specialty Clinics
6.2.2 Homecare
6.2.3 Hospitals
6.3 Market Attractiveness Analysis by End User
Chapter 7 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Route of Administration
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Route of Administration
7.1.2 Basis Point Share (BPS) Analysis by Route of Administration
7.1.3 Absolute $ Opportunity Assessment by Route of Administration
7.2 HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
7.2.1 Oral
7.2.2 Parenteral
7.3 Market Attractiveness Analysis by Route of Administration
Chapter 8 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Distribution Channel
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Distribution Channel
8.1.2 Basis Point Share (BPS) Analysis by Distribution Channel
8.1.3 Absolute $ Opportunity Assessment by Distribution Channel
8.2 HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
8.2.1 Hospital Pharmacy
8.2.2 Retail Pharmacy
8.2.3 Online Pharmacy
8.3 Market Attractiveness Analysis by Distribution Channel
Chapter 9 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 HER2-Positive Breast Cancer Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America HER2-Positive Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 North America HER2-Positive Breast Cancer Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
11.6.1 Chemotherapy
11.6.2 Targeted Therapy Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Treatment Type
11.8 Absolute $ Opportunity Assessment by Treatment Type
11.9 Market Attractiveness Analysis by Treatment Type
11.10 North America HER2-Positive Breast Cancer Market Size Forecast by End User
11.10.1 Specialty Clinics
11.10.2 Homecare
11.10.3 Hospitals
11.11 Basis Point Share (BPS) Analysis by End User
11.12 Absolute $ Opportunity Assessment by End User
11.13 Market Attractiveness Analysis by End User
11.14 North America HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
11.14.1 Oral
11.14.2 Parenteral
11.15 Basis Point Share (BPS) Analysis by Route of Administration
11.16 Absolute $ Opportunity Assessment by Route of Administration
11.17 Market Attractiveness Analysis by Route of Administration
11.18 North America HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
11.18.1 Hospital Pharmacy
11.18.2 Retail Pharmacy
11.18.3 Online Pharmacy
11.19 Basis Point Share (BPS) Analysis by Distribution Channel
11.20 Absolute $ Opportunity Assessment by Distribution Channel
11.21 Market Attractiveness Analysis by Distribution Channel
Chapter 12 Europe HER2-Positive Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Europe HER2-Positive Breast Cancer Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
12.6.1 Chemotherapy
12.6.2 Targeted Therapy Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Treatment Type
12.8 Absolute $ Opportunity Assessment by Treatment Type
12.9 Market Attractiveness Analysis by Treatment Type
12.10 Europe HER2-Positive Breast Cancer Market Size Forecast by End User
12.10.1 Specialty Clinics
12.10.2 Homecare
12.10.3 Hospitals
12.11 Basis Point Share (BPS) Analysis by End User
12.12 Absolute $ Opportunity Assessment by End User
12.13 Market Attractiveness Analysis by End User
12.14 Europe HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
12.14.1 Oral
12.14.2 Parenteral
12.15 Basis Point Share (BPS) Analysis by Route of Administration
12.16 Absolute $ Opportunity Assessment by Route of Administration
12.17 Market Attractiveness Analysis by Route of Administration
12.18 Europe HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
12.18.1 Hospital Pharmacy
12.18.2 Retail Pharmacy
12.18.3 Online Pharmacy
12.19 Basis Point Share (BPS) Analysis by Distribution Channel
12.20 Absolute $ Opportunity Assessment by Distribution Channel
12.21 Market Attractiveness Analysis by Distribution Channel
Chapter 13 Asia Pacific HER2-Positive Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
13.6.1 Chemotherapy
13.6.2 Targeted Therapy Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Treatment Type
13.8 Absolute $ Opportunity Assessment by Treatment Type
13.9 Market Attractiveness Analysis by Treatment Type
13.10 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by End User
13.10.1 Specialty Clinics
13.10.2 Homecare
13.10.3 Hospitals
13.11 Basis Point Share (BPS) Analysis by End User
13.12 Absolute $ Opportunity Assessment by End User
13.13 Market Attractiveness Analysis by End User
13.14 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
13.14.1 Oral
13.14.2 Parenteral
13.15 Basis Point Share (BPS) Analysis by Route of Administration
13.16 Absolute $ Opportunity Assessment by Route of Administration
13.17 Market Attractiveness Analysis by Route of Administration
13.18 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
13.18.1 Hospital Pharmacy
13.18.2 Retail Pharmacy
13.18.3 Online Pharmacy
13.19 Basis Point Share (BPS) Analysis by Distribution Channel
13.20 Absolute $ Opportunity Assessment by Distribution Channel
13.21 Market Attractiveness Analysis by Distribution Channel
Chapter 14 Latin America HER2-Positive Breast Cancer Analysis and Forecast
14.1 Introduction
14.2 Latin America HER2-Positive Breast Cancer Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
14.6.1 Chemotherapy
14.6.2 Targeted Therapy Immunotherapy
14.7 Basis Point Share (BPS) Analysis by Treatment Type
14.8 Absolute $ Opportunity Assessment by Treatment Type
14.9 Market Attractiveness Analysis by Treatment Type
14.10 Latin America HER2-Positive Breast Cancer Market Size Forecast by End User
14.10.1 Specialty Clinics
14.10.2 Homecare
14.10.3 Hospitals
14.11 Basis Point Share (BPS) Analysis by End User
14.12 Absolute $ Opportunity Assessment by End User
14.13 Market Attractiveness Analysis by End User
14.14 Latin America HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
14.14.1 Oral
14.14.2 Parenteral
14.15 Basis Point Share (BPS) Analysis by Route of Administration
14.16 Absolute $ Opportunity Assessment by Route of Administration
14.17 Market Attractiveness Analysis by Route of Administration
14.18 Latin America HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
14.18.1 Hospital Pharmacy
14.18.2 Retail Pharmacy
14.18.3 Online Pharmacy
14.19 Basis Point Share (BPS) Analysis by Distribution Channel
14.20 Absolute $ Opportunity Assessment by Distribution Channel
14.21 Market Attractiveness Analysis by Distribution Channel
Chapter 15 Middle East & Africa (MEA) HER2-Positive Breast Cancer Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
15.6.1 Chemotherapy
15.6.2 Targeted Therapy Immunotherapy
15.7 Basis Point Share (BPS) Analysis by Treatment Type
15.8 Absolute $ Opportunity Assessment by Treatment Type
15.9 Market Attractiveness Analysis by Treatment Type
15.10 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by End User
15.10.1 Specialty Clinics
15.10.2 Homecare
15.10.3 Hospitals
15.11 Basis Point Share (BPS) Analysis by End User
15.12 Absolute $ Opportunity Assessment by End User
15.13 Market Attractiveness Analysis by End User
15.14 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
15.14.1 Oral
15.14.2 Parenteral
15.15 Basis Point Share (BPS) Analysis by Route of Administration
15.16 Absolute $ Opportunity Assessment by Route of Administration
15.17 Market Attractiveness Analysis by Route of Administration
15.18 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
15.18.1 Hospital Pharmacy
15.18.2 Retail Pharmacy
15.18.3 Online Pharmacy
15.19 Basis Point Share (BPS) Analysis by Distribution Channel
15.20 Absolute $ Opportunity Assessment by Distribution Channel
15.21 Market Attractiveness Analysis by Distribution Channel
Chapter 16 Competition Landscape
16.1 HER2-Positive Breast Cancer Market: Competitive Dashboard
16.2 Global HER2-Positive Breast Cancer Market: Market Share Analysis, 2019
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Bayer AG
16.3.2 Fresenius Kabi AG
16.3.3 F. Hoffmann-La Roche Ltd.
16.3.4 Teva Pharmaceuticals Industries Ltd.
16.3.5 Baxter
16.3.6 Mylan N.V.
16.3.7 GlaxoSmithKline plc.
16.3.8 Pfizer Inc.
16.3.9 Merck & Co. Inc.
16.3.10 Takeda Pharmaceutical Company Limited
16.3.11 Eli Lilly and Company
16.3.12 AstraZeneca
16.3.13 Novartis AG
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HER2-Positive Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 HER2-Positive Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 HER2-Positive Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the HER2-Positive Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global HER2-Positive Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 HER2-Positive Breast Cancer Market Size and Y-o-Y Growth
4.5.2 HER2-Positive Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Treatment Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Treatment Type
5.1.2 Basis Point Share (BPS) Analysis by Treatment Type
5.1.3 Absolute $ Opportunity Assessment by Treatment Type
5.2 HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy Immunotherapy
5.3 Market Attractiveness Analysis by Treatment Type
Chapter 6 Global HER2-Positive Breast Cancer Market Analysis and Forecast by End User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End User
6.1.2 Basis Point Share (BPS) Analysis by End User
6.1.3 Absolute $ Opportunity Assessment by End User
6.2 HER2-Positive Breast Cancer Market Size Forecast by End User
6.2.1 Specialty Clinics
6.2.2 Homecare
6.2.3 Hospitals
6.3 Market Attractiveness Analysis by End User
Chapter 7 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Route of Administration
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Route of Administration
7.1.2 Basis Point Share (BPS) Analysis by Route of Administration
7.1.3 Absolute $ Opportunity Assessment by Route of Administration
7.2 HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
7.2.1 Oral
7.2.2 Parenteral
7.3 Market Attractiveness Analysis by Route of Administration
Chapter 8 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Distribution Channel
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Distribution Channel
8.1.2 Basis Point Share (BPS) Analysis by Distribution Channel
8.1.3 Absolute $ Opportunity Assessment by Distribution Channel
8.2 HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
8.2.1 Hospital Pharmacy
8.2.2 Retail Pharmacy
8.2.3 Online Pharmacy
8.3 Market Attractiveness Analysis by Distribution Channel
Chapter 9 Global HER2-Positive Breast Cancer Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 HER2-Positive Breast Cancer Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America HER2-Positive Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 North America HER2-Positive Breast Cancer Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
11.6.1 Chemotherapy
11.6.2 Targeted Therapy Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Treatment Type
11.8 Absolute $ Opportunity Assessment by Treatment Type
11.9 Market Attractiveness Analysis by Treatment Type
11.10 North America HER2-Positive Breast Cancer Market Size Forecast by End User
11.10.1 Specialty Clinics
11.10.2 Homecare
11.10.3 Hospitals
11.11 Basis Point Share (BPS) Analysis by End User
11.12 Absolute $ Opportunity Assessment by End User
11.13 Market Attractiveness Analysis by End User
11.14 North America HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
11.14.1 Oral
11.14.2 Parenteral
11.15 Basis Point Share (BPS) Analysis by Route of Administration
11.16 Absolute $ Opportunity Assessment by Route of Administration
11.17 Market Attractiveness Analysis by Route of Administration
11.18 North America HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
11.18.1 Hospital Pharmacy
11.18.2 Retail Pharmacy
11.18.3 Online Pharmacy
11.19 Basis Point Share (BPS) Analysis by Distribution Channel
11.20 Absolute $ Opportunity Assessment by Distribution Channel
11.21 Market Attractiveness Analysis by Distribution Channel
Chapter 12 Europe HER2-Positive Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Europe HER2-Positive Breast Cancer Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
12.6.1 Chemotherapy
12.6.2 Targeted Therapy Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Treatment Type
12.8 Absolute $ Opportunity Assessment by Treatment Type
12.9 Market Attractiveness Analysis by Treatment Type
12.10 Europe HER2-Positive Breast Cancer Market Size Forecast by End User
12.10.1 Specialty Clinics
12.10.2 Homecare
12.10.3 Hospitals
12.11 Basis Point Share (BPS) Analysis by End User
12.12 Absolute $ Opportunity Assessment by End User
12.13 Market Attractiveness Analysis by End User
12.14 Europe HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
12.14.1 Oral
12.14.2 Parenteral
12.15 Basis Point Share (BPS) Analysis by Route of Administration
12.16 Absolute $ Opportunity Assessment by Route of Administration
12.17 Market Attractiveness Analysis by Route of Administration
12.18 Europe HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
12.18.1 Hospital Pharmacy
12.18.2 Retail Pharmacy
12.18.3 Online Pharmacy
12.19 Basis Point Share (BPS) Analysis by Distribution Channel
12.20 Absolute $ Opportunity Assessment by Distribution Channel
12.21 Market Attractiveness Analysis by Distribution Channel
Chapter 13 Asia Pacific HER2-Positive Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
13.6.1 Chemotherapy
13.6.2 Targeted Therapy Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Treatment Type
13.8 Absolute $ Opportunity Assessment by Treatment Type
13.9 Market Attractiveness Analysis by Treatment Type
13.10 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by End User
13.10.1 Specialty Clinics
13.10.2 Homecare
13.10.3 Hospitals
13.11 Basis Point Share (BPS) Analysis by End User
13.12 Absolute $ Opportunity Assessment by End User
13.13 Market Attractiveness Analysis by End User
13.14 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
13.14.1 Oral
13.14.2 Parenteral
13.15 Basis Point Share (BPS) Analysis by Route of Administration
13.16 Absolute $ Opportunity Assessment by Route of Administration
13.17 Market Attractiveness Analysis by Route of Administration
13.18 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
13.18.1 Hospital Pharmacy
13.18.2 Retail Pharmacy
13.18.3 Online Pharmacy
13.19 Basis Point Share (BPS) Analysis by Distribution Channel
13.20 Absolute $ Opportunity Assessment by Distribution Channel
13.21 Market Attractiveness Analysis by Distribution Channel
Chapter 14 Latin America HER2-Positive Breast Cancer Analysis and Forecast
14.1 Introduction
14.2 Latin America HER2-Positive Breast Cancer Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
14.6.1 Chemotherapy
14.6.2 Targeted Therapy Immunotherapy
14.7 Basis Point Share (BPS) Analysis by Treatment Type
14.8 Absolute $ Opportunity Assessment by Treatment Type
14.9 Market Attractiveness Analysis by Treatment Type
14.10 Latin America HER2-Positive Breast Cancer Market Size Forecast by End User
14.10.1 Specialty Clinics
14.10.2 Homecare
14.10.3 Hospitals
14.11 Basis Point Share (BPS) Analysis by End User
14.12 Absolute $ Opportunity Assessment by End User
14.13 Market Attractiveness Analysis by End User
14.14 Latin America HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
14.14.1 Oral
14.14.2 Parenteral
14.15 Basis Point Share (BPS) Analysis by Route of Administration
14.16 Absolute $ Opportunity Assessment by Route of Administration
14.17 Market Attractiveness Analysis by Route of Administration
14.18 Latin America HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
14.18.1 Hospital Pharmacy
14.18.2 Retail Pharmacy
14.18.3 Online Pharmacy
14.19 Basis Point Share (BPS) Analysis by Distribution Channel
14.20 Absolute $ Opportunity Assessment by Distribution Channel
14.21 Market Attractiveness Analysis by Distribution Channel
Chapter 15 Middle East & Africa (MEA) HER2-Positive Breast Cancer Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Treatment Type
15.6.1 Chemotherapy
15.6.2 Targeted Therapy Immunotherapy
15.7 Basis Point Share (BPS) Analysis by Treatment Type
15.8 Absolute $ Opportunity Assessment by Treatment Type
15.9 Market Attractiveness Analysis by Treatment Type
15.10 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by End User
15.10.1 Specialty Clinics
15.10.2 Homecare
15.10.3 Hospitals
15.11 Basis Point Share (BPS) Analysis by End User
15.12 Absolute $ Opportunity Assessment by End User
15.13 Market Attractiveness Analysis by End User
15.14 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Route of Administration
15.14.1 Oral
15.14.2 Parenteral
15.15 Basis Point Share (BPS) Analysis by Route of Administration
15.16 Absolute $ Opportunity Assessment by Route of Administration
15.17 Market Attractiveness Analysis by Route of Administration
15.18 Middle East & Africa (MEA) HER2-Positive Breast Cancer Market Size Forecast by Distribution Channel
15.18.1 Hospital Pharmacy
15.18.2 Retail Pharmacy
15.18.3 Online Pharmacy
15.19 Basis Point Share (BPS) Analysis by Distribution Channel
15.20 Absolute $ Opportunity Assessment by Distribution Channel
15.21 Market Attractiveness Analysis by Distribution Channel
Chapter 16 Competition Landscape
16.1 HER2-Positive Breast Cancer Market: Competitive Dashboard
16.2 Global HER2-Positive Breast Cancer Market: Market Share Analysis, 2019
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Bayer AG
16.3.2 Fresenius Kabi AG
16.3.3 F. Hoffmann-La Roche Ltd.
16.3.4 Teva Pharmaceuticals Industries Ltd.
16.3.5 Baxter
16.3.6 Mylan N.V.
16.3.7 GlaxoSmithKline plc.
16.3.8 Pfizer Inc.
16.3.9 Merck & Co. Inc.
16.3.10 Takeda Pharmaceutical Company Limited
16.3.11 Eli Lilly and Company
16.3.12 AstraZeneca
16.3.13 Novartis AG
Segments Covered in the Report
The global HER2-Positive Breast Cancer market has been segmented based on
By Treatment Type
The global HER2-Positive Breast Cancer market has been segmented based on
By Treatment Type
- Chemotherapy
- Targeted Therapy Immunotherapy
- Specialty Clinics
- Homecare
- Hospitals
- Oral
- Parenteral
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Bayer AG
- Fresenius Kabi AG
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Baxter
- Mylan N.V.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Merck & Co. Inc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- AstraZeneca
- Novartis AG
Our Clients
Related Reports
Some other reports from this category!
